It has been estimated that around 10% of total bone mass is renewed per year leading to a full replacement of the bone tissue every 10 years. This biological mechanism called “bone remodeling” plays a central role in calcium and phosphorus homeostasis and is the result of a balance between osteoclast and osteoblast activities. Indeed, osteoclasts originating from hematopoietic stem cells resorb bone (Rousselle and Heymann 2002); and in contrast, osteoblasts, which come from mesenchymal stem cells, are specialized in the formation of new mineralized extracellular matrix (Dechaseaux et al. 2009). For many years, a central regulation based on hormone network including parathyroid hormone (PTH) or calcitonin has been considered as the key...
KeywordsVascular Calcification Osteoclast Differentiation Necrosis Factor Receptor Superfamily Member Cancer Stem Cell Pool Master Protein
- Davaine JM, Quillard T, Chatelais M, Guilbaud F, Brion R, Guyomarch B, et al. Bone like arterial calcification in femoral atherosclerotic lesions: prevalence and role of osteoprotegerin and pericytes. Eur J Vasc Endovasc Surg. 2016;51:259–67. doi:10.1016/j.ejvs.2015.10.004.CrossRefPubMedGoogle Scholar
- Kondegowda NG, Fenutria R, Pollack IR, Orthofer M, Garcia-Ocaña A, Penninger JM, et al. Osteoprotegerin and denosumab stimulate human beta cell proliferation through inhibition of the receptor activator of NF-κB ligand pathway. Cell Metab. 2015;22:77–85. doi:10.1016/j.cmet.2015.05.021.CrossRefPubMedPubMedCentralGoogle Scholar
- Théoleyre S, Kwan Tat S, Vusio P, Blanchard F, Gallagher J, Ricard-Blum S, et al. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. Biochem Biophys Res Commun. 2006;347:460–7. doi:10.1016/j.bbrc.2006.06.120.CrossRefPubMedGoogle Scholar
- Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 1998a;139:1329–37. doi:10.1210/endo.139.3.5837.PubMedGoogle Scholar